HIV Prevention Clinical Trials Database

A comprehensive source of information on biomedical HIV prevention clinical trials

View Trials Map

Our database allows users to view planned, ongoing, and completed clinical trials around the world, gaining an understanding of the many developments currently being made in the field of HIV prevention research.

Search or Filter

Reset filters

Results

showing 1-20 of 98

Trial Name

Cabotegravir implant (Preclinical)

Completed
Prevention Option
Microbicides, PrEP
Start Date
End Date
Population
Cisgender Men
Country
United States of America
Product Candidate
Cabotegravir (GSK 744)
Sponsors
NIAID
Trial Name

Population Council #728

Completed
Prevention Option
Microbicides
Start Date
October 6, 2017
End Date
September 5, 2018
Population
Cisgender Women
Country
United States of America
Product Candidate
PC-6500, JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Trial Name

CLIP Ring

Prevention Option
Microbicides, MPTs
Start Date
December 1, 2019
End Date
November 30, 2024
Population
Cisgender Men
Product Candidate
Islatravir (MK-8591)
Sponsors
CDC, NIAID
Trial Name

MTN-044/IPM 053/ CCN019

Completed
Prevention Option
Microbicides, MPTs
Start Date
July 17, 2018
End Date
October 7, 2019
Population
Cisgender Women
Country
United States of America
Product Candidate
Dapivirine-Levonorgestrel ring
Trial Name

PREVENT study

Prevention Option
Microbicides
Start Date
July 10, 2019
End Date
February 4, 2021
Population
Cisgender Men, Cisgender Women
Product Candidate
Q-GRFT, JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
Intrucept Biomedicine LLC, NIAID, Rhonda Brand
Trial Name

FAME103

Ongoing
Prevention Option
Microbicides
Start Date
August 19, 2020
End Date
August 25, 2022
Population
Cisgender Women
Country
United States of America
Product Candidate
MK-2048
Sponsors
NIAID (STUDY19100120)
Trial Name

ImQuest DuoGel

Completed
Prevention Option
Microbicides
Start Date
November 1, 2017
End Date
June 2, 2019
Population
Cisgender Men, Cisgender Women
Country
United States of America
Product Candidate
IQP-0528
Trial Name

CONRAD A15-138/ ENRICH

Completed
Prevention Option
Microbicides, MPTs
Start Date
September 5, 2017
End Date
December 26, 2018
Population
Cisgender Men
Country
Dominican Republic, United States of America
Product Candidate
TFV/LNG ring, JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
CONRAD
Trial Name

mAb 2C7 + TDF IVR

Ongoing
Prevention Option
Microbicides
Start Date
April 1, 2018
End Date
March 1, 2023
Population
Cisgender Men
Product Candidate
TDF
Trial Name

MTN 043/ B-PROTECTED

Completed
Prevention Option
Microbicides
Start Date
August 24, 2020
End Date
November 4, 2021
Population
Adolescents and Young People, Cisgender Women, Pregnant and Lactating Populations
Country
Malawi, South Africa, Uganda, Zimbabwe
Product Candidate
Dapivirine Ring, TDF/FTC (Truvada)
Sponsors
NIAID (DAIDS-ES: 38591)
Trial Name

OB-002H

Completed
Prevention Option
Microbicides
Start Date
October 5, 2019
End Date
August 31, 2020
Population
Cisgender Women, Gay and Bisexual Men Who Have Sex with Men
Country
Poland
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
SCOPE International AG
Trial Name

CONRAD A15-140

Completed
Prevention Option
Microbicides, PrEP
Start Date
April 7, 2016
End Date
August 5, 2016
Population
Cisgender Women
Country
United States of America
Product Candidate
TFV ring, TDF/FTC (Truvada)
Trial Name

MTN-041/ MAMMA

Ongoing
Prevention Option
Microbicides, PrEP
Start Date
May 31, 2018
End Date
November 2, 2018
Population
Cisgender Women
Country
Malawi, South Africa, Uganda, Zimbabwe
Product Candidate
TDF/FTC (Truvada), Dapivirine Ring
Sponsors
NIAID (DAIDS-ES: 38161)
Trial Name

Novel mAb contraceptive + TDF IVR

Ongoing
Prevention Option
Microbicides
Start Date
May 2, 2020
End Date
February 21, 2021
Population
Product Candidate
TDF
Sponsors
NICHD
Trial Name

MTN-003C (VOICE Community Substudy)

Completed
Prevention Option
Microbicides, PrEP
Start Date
June 15, 2010
End Date
July 18, 2012
Population
Cisgender Women
Country
South Africa
Sponsors
DAIDS, NIAID, NIH
Trial Name

CONRAD B17-144

Ongoing
Prevention Option
Microbicides, MPTs
Start Date
December 6, 2018
End Date
April 2, 2020
Population
Cisgender Women
Country
Kenya
Product Candidate
TFV/LNG ring, TFV ring, JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Trial Name

Amphora/QGriffithsin (QGRFT) fast-dissolving vaginal insert (FDI)

Prevention Option
Microbicides
Start Date
May 24, 2021
End Date
May 24, 2021
Population
Product Candidate
Q-GRFT
Sponsors
NIAID
Trial Name

90-day Pod-type Etonogestrel/Ethinyl Estradiol/QGriffithsin (QGRFT) Intravaginal Ring [EEQ IVR]

Ongoing
Prevention Option
Microbicides
Start Date
April 7, 2020
End Date
March 31, 2025
Population
Product Candidate
Q-GRFT
Sponsors
NIAID
Trial Name

CONRAD A18-146

Completed
Prevention Option
Microbicides, MPTs
Start Date
December 11, 2018
End Date
March 20, 2019
Population
Cisgender Women
Country
United States of America
Product Candidate
F/TAF, Elvitegravir (EVG)
Sponsors
CONRAD
Trial Name

Pop Council PC-6500 Vaginal insert

Prevention Option
Microbicides
Start Date
March 1, 2018
End Date
July 2, 2018
Population
Cisgender Women
Product Candidate
PC-6500

showing 1-20 of 98